Skip to main content
Eric Rowinsky, MD, Oncology, Boca Raton, FL

EricKeithRowinskyMD

Oncology • Boca Raton, FL

Breast Cancer, Gastrointestinal Cancer, Clinical Pharmacology

President, Inspirna Inc; Consulting CMO, Biocity, Inc.; Board of Directors, Biogen, Purple Bio, Verastem, Fortress Bio, Inspirna

Join to view full profile

Dr. Rowinsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rowinsky's full profile

Already have an account?

Summary

  • Focus is on the development of cancer therapeutics and novel treatments in other therapeutic indications in the biotechnology industry. Develop developmental strategies for novel therapeutics and incorporate such into corporate strategies. Asset and corporate evaluations for biopharma and investors.

Education & Training

  • Vanderbilt University School of Medicine
    Vanderbilt University School of MedicineClass of 1981

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1996 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies
    Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid MalignanciesDecember 6th, 2021
  • Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
    Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of DirectorsMay 19th, 2021
  • Shanghai Genechem Co., Ltd. (Genechem) Announces Appointment of Dr. Eric Rowinsky and Dr. Manuel Hidalgo to Scientific Advisory Board, and Abstract Presentation at AACR 2021 on Claudin 6 Ab and K-ras TCR-T
    Shanghai Genechem Co., Ltd. (Genechem) Announces Appointment of Dr. Eric Rowinsky and Dr. Manuel Hidalgo to Scientific Advisory Board, and Abstract Presentation at AACR 2021 on Claudin 6 Ab and K-ras TCR-TApril 8th, 2021
  • Join now to see all

Grant Support

  • Phase II Pharmacologic/Biologic Study Of ThalidomideNational Center For Research Resources2004
  • PH I Study Of BMS-247550 In PTS With Advanced NeoplasmsNational Center For Research Resources2004
  • PH I Pharmacokinetics Of Nsc-655649/Cisplatin/G-CsfNational Center For Research Resources2004
  • Phase I Clinical Trials Of Anti-Cancer AgentsNational Cancer Institute2003
  • ERBB1 And ERBB2 Blockade In Advanced Breast CancerNational Cancer Institute2003
  • Phase II Trial Of DX 8951f In Hepatocellular CarcinomaNational Center For Research Resources2000–2002
  • Pharmacokinetic Trial Of Weekly Docetaxel In Solid TumorNational Center For Research Resources2000–2002
  • Pharmacokinetic Study Of Troxacitabine And CisplatinNational Center For Research Resources2000–2002
  • IV Dx8951f In Patients With Advanced Solid TumorsNational Center For Research Resources2000–2002
  • Intoplicine Pharmacokinetics--Continuous 5 Day 4 Wk DoseNational Center For Research Resources2000–2002
  • Combination Paclitaxel/L778,123 In Solid TumorsNational Center For Research Resources2000–2002
  • Trial Of Zeneca ZD9331 Given As An Oral TabletNational Center For Research Resources1999–2002
  • Sch52365: Phase I Study Of Cyclic Oral AdministrationNational Center For Research Resources1999–2002
  • Phase I Trial Of LY231514 W/ IrinotecanNational Center For Research Resources1999–2002
  • Phase I Trial Of LY231514 In Patients W/ Varying Degrees Of Renal FunctionNational Center For Research Resources1999–2002
  • Phase I Trial Of Bizelesin Using Single Bolus Infusion Every 28 DaysNational Center For Research Resources1999–2002
  • Phase I Study Of CP 358,774 In Subjects W/ Advanced Solid TumorsNational Center For Research Resources1999–2002
  • Phase I Study Of CCI 779 In Patients W/ Advanced Solid TumorsNational Center For Research Resources1999–2002
  • Phase I Study Of Bms 184476 In Patients W/ Advanced MalignanciesNational Center For Research Resources1999–2002
  • 7 Day Continuous Infusion Of L778123 In Recurrent MalignanciesNational Center For Research Resources1999–2002
  • Phase I Pharmacokinetic Study Of Bch 4556National Center For Research Resources1998–2002
  • Phase I Dose Escalation Trial Of Zeneca ZD9331National Center For Research Resources1998–2002
  • Phase I Clinical Trials Of Anticancer AgentsNational Cancer Institute1998–2002
  • Phase I Study Of IV Dx88951f Given Daily For 5 Days Every 3 WeeksNational Center For Research Resources1999–2000
  • Phase I Study Of Combined 776c85 &5 FU Tablet &5 FU TabletsNational Center For Research Resources1999–2000
  • Phase I Study Of Docetaxel And Doxorubicin Combination ChemotherapyNational Center For Research Resources1998–1999
  • Absorption, Metabolism, Excretion Of SCH 52365 (Temozolomide)In Advanced CancerNational Center For Research Resources1997
  • Human Metabolism Of TaxolNational Cancer Institute1991–1993

Dr. Eric Rowinsky, Dr. Eric Rowinsky, MD, Dr. E Rowinsky, Dr. Eric Keith Rowinsky